鉴定β-arrestin偏向的负基调节器用于β-上腺素受体
Michael Ippolito1, Francesco De Pascali1, Nathan Hopfinger1
1Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
研究人员开发了一种新型化合物DFPQ,可以选择性地阻止β-arrestin与β-上腺素受体 (AR) 的相互作用. 这种偏向的全调节器增强了治疗性β2AR信号,同时防止了无敏化,为呼吸道疾病治疗提供了新的策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 接收器信号传输 接收器信号传输
背景情况:
- β-上腺素受体 (β-AR) 信号传递对于生理功能和喘治疗至关重要.
- GRKs和β-arrestins对β2AR信号进行负面调节,导致无敏化和相反的治疗效果.
- 针对β2AR有利于Gs-蛋白结合而不是β-arrestin招募,可以提高治疗疗效.
研究的目的:
- 为了识别选择性抑制β-arrestin招募到β2AR的小分子.
- 为改进β2AR介导疗法开发偏向的全调节剂.
主要方法:
- 对小分子库进行选,以寻找β-止素招募的抑制剂.
- 使用生物化学和细胞分析对已识别的化合物进行表征.
- 结构研究包括建模和突变发生,以确定结合部位.
主要成果:
- 一种二甲基纳林 (DFPQ) 衍生物被确定为选择性负基调节器,用于将β-arrestin招募到β2AR.
- DFPQ没有影响β2AR与Gs蛋白质的合.
- 在细胞和组织模型中,DFPQ抑制了β2AR酸化,内化和脱敏,对β2AR超过β1AR具有特异性.
结论:
- DFPQ代表了一种新型的偏向性全调节器类,其向β2AR上的全位.
- DFPQ的机制提供了一种潜在的策略,通过将它们与有害的β-阿雷斯介导作用脱,来增强β2AR激动剂的治疗益处.
- 进一步开发DFPQ衍生物可能会导致改善呼吸道疾病的治疗方法.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
09:03Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
Published on: March 10, 2020
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
